Cost of Metabolic Dysfunction-Associated Steatotic Liver Disease Screening Among All People Living With Diabetes in Six Countries

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent among people living with type 2 diabetes, with estimated rates of 65.4% and 31.6%, respectively, globally. This study aimed to esti...

Descripción completa

Detalles Bibliográficos
Autores: Lazarus, Jeffrey V.|||0000-0001-9618-2299, Agirre-Garrido, Leire, Miralles-Sanchez, J. Emilio, Manolas, Melina I., Tacke, Frank|||0000-0001-6206-0226, Villela-Nogueira, Cristiane A., Al-Omar, Hussain Abdulrahman|||0000-0002-0765-0466, Alqahtani, Saleh|||0000-0003-2017-3526, Alzubaidi, Lamya Mohammed Yahya, Bansal, Meena|||0000-0002-7501-2191, Cusi, Kenneth|||0000-0002-8629-418X, Isaacs, Scott D., Mauricio, Didac|||0000-0002-2868-0250, Miyake, Teruki|||0000-0002-9905-5356, Moreira, Rodrigo O.|||0000-0003-1561-2926, Nakazawa, Shoko|||0000-0002-9639-6809, Pannain, Silvana|||0000-0001-7793-8951, Pericàs, Juan M.|||0000-0002-3645-3293, Roden, Michael|||0000-0001-8200-6382, Takahashi, Hirokazu, Brachowicz, Nicolai
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:dnet:uabarcelona_::06b0e8238f9085b579a2840e4af6e1e5
Acceso en línea:https://ddd.uab.cat/record/328203
https://dx.doi.org/urn:doi:10.1111/liv.70390
Access Level:acceso abierto
Palabra clave:MASH
MASLD
Metabolic health
National health accounts
Non-invasive testing
Strategic budgeting
Descripción
Sumario:Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent among people living with type 2 diabetes, with estimated rates of 65.4% and 31.6%, respectively, globally. This study aimed to estimate the direct healthcare costs of two MASLD and MASH screening strategies among all people living with diabetes in Brazil, Germany, Japan, the Kingdom of Saudi Arabia (KSA), Spain and the United States (US), from 2026 to 2030. Strategy 1 consisted of a one-time universal screening of all adults living with diabetes. Strategy 2 involved biennial retesting of individuals who initially tested negative. The Fibrosis-4 (FIB-4) index was used as the first line test, followed by the Enhanced Liver Fibrosis (ELF) test or vibration-controlled transient elastography (VCTE) for confirmatory assessment. Implementation costs were estimated based on the country-specific prevalence of diabetes and included positive price variations that were aligned to monetary policy targets. Over 5 years, the estimated costs of Strategy 1 ranged from R.

Similares en LA Referencia